Ozempic's mechanism and side effects: what TikTok gets right and wrong

What did @drtopal actually say?

Honestly? It is nearly impossible to tell. The transcript provided for this video is incoherent, and does not contain a single identifiable claim about Ozempic, GLP-1 receptor agonists, semaglutide, or any related medication. The text references Poland, war, virus control, and making videos that look like doctors. None of that maps onto the stated topic of Ozempic's mechanism and side effects.

The caption promises a breakdown of Ozempic's mechanism and side effects. The transcript delivers nothing of the sort. Whether this is a transcription failure, a dubbed-over audio issue, or something else entirely, the content as recorded cannot be evaluated for medical accuracy because no medical content is discernible. That is a problem in itself, and worth flagging before anything else.

Does the science back this up?

Since no verifiable claims about Ozempic appear in the transcript, there is nothing to confirm or refute against the clinical literature. What we can do is lay out what a legitimate video on this topic should say, so you have a baseline for comparison.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021). It works by mimicking the endogenous hormone glucagon-like peptide-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite via central nervous system pathways. The SUSTAIN and STEP trial series, published across multiple years in the New England Journal of Medicine, established both glycemic efficacy and weight reduction of up to 15 percent of body weight at 2.4 mg weekly dosing (Wilding et al., 2021, NEJM). Side effects documented in those trials include nausea, vomiting, diarrhea, constipation, and a black-box warning for thyroid C-cell tumors in rodent studies.

What did they get wrong (or right)?

There is no way to credit or criticize @drtopal for specific Ozempic claims because none appear in the provided transcript. That is not a technicality. If a video is captioned as medical education about a widely-used drug, and the spoken content is unrelated or unintelligible, that is a content integrity failure regardless of intent.

The creator does include a disclaimer in the caption: "Bu video bilgilendirme amacı taşımakta olup tedaviler için lütfen doktorunuza danışınız" (this video is for informational purposes only, please consult your doctor for treatments). That is good practice and worth acknowledging. But a disclaimer does not compensate for content that cannot be evaluated. With 28,500 views, whatever was actually said in this video has reached a meaningful audience on a topic where misinformation carries real clinical risk.

What should you actually know?

If you watched this video hoping to learn about Ozempic, here is what the peer-reviewed literature actually says. Semaglutide does not cure diabetes or obesity. It manages them, and only while you are taking it. Wilding et al. (2022, Diabetes Care) showed that most weight lost during STEP 1 was regained within one year of stopping the drug. That is not a failure of the drug. It reflects the chronic nature of both conditions.

Common side effects are mostly gastrointestinal and tend to be worst in the first few weeks of treatment. Serious but rarer events include pancreatitis, gallbladder disease, and heart rate increases. The thyroid tumor risk observed in rodents has not been confirmed in humans, but semaglutide is still contraindicated in people with a personal or family history of medullary thyroid carcinoma (FDA prescribing information, 2023).

Compounded semaglutide products are not equivalent to FDA-approved Ozempic or Wegovy. The FDA has explicitly warned about this. Do not assume they are interchangeable.

• Always discuss dosing adjustments with a licensed prescriber.
• Side effects are real and should be reported, not tolerated silently.
• Weight regain after stopping is the norm, not the exception.

Should you trust this video?

Based on the available transcript, there is no medical content to trust or distrust. The mismatch between the caption's promise and the transcript's content is significant enough that viewers should seek out better-sourced information before making any decisions about GLP-1 therapy. A licensed telehealth provider or endocrinologist remains the appropriate first stop for questions about semaglutide.